Table 2
From the following article
Brazilian health biotech—fostering crosstalk between public and private sectors
Rahim Rezaie, Sarah E Frew, Stephen M Sammut, Maya R Maliakkal, Abdallah S Daar & Peter A Singer
Nature Biotechnology 26, 627 - 644 (2008)
doi:10.1038/nbt0608-627
Table 2. Financial background for companies intervieweda
| Company name | Year founded | Public or private | Approximate revenues (millions Brazilian reais (R$) or US dollars ($)) | Grants or low-interest loans from governmental sources (millions Brazilian reais (R$) or US dollars ($)) | Sources of private investment/amounts (millions Brazilian reais (R$) or US dollars ($)) | Revenues from exports (millions Brazilian reais (R$) or US dollars ($)) | Approximate R&D expenditure annually or as statedb (millions Brazilian reais (R$) or US dollars ($)) | Total number of employees (involved in R&D where available) |
|---|---|---|---|---|---|---|---|---|
aSome figures were provided to us in US dollars, others in Brazilian reais (R$). For consistency, data are presented in both currencies using an exchange rate of $1 being equal to | ||||||||
bR&D expenditure is not limited to activities related to novel product development; four digit numbers in parentheses. | ||||||||
cBiolab and União Química Farmacêutica Nacional are both owned by Castro Marques Group. | ||||||||
dCryopraxis Criobiologia is a spin-off of Silvestre Laboratories and has now established its own subsidiary in the United States called CellPraxis USA Inc. (Jupiter, FL, USA). | ||||||||
eRSTec Venture Fund is a joint creation of Inter-American Development Bank, Brazilian Development Bank (BNDES) and other individuals and programs. | ||||||||
fSince the interview, Katal Biotecnológica has been taken over by Interteck International Imp. e Exp. (São Paulo), a former shareholder, and its founder Leonides Rezende has started a new firm focused on molecular diagnostics. N/A, data not available or not disclosed; FINEP, Financiadora de Estudos e Projetos–Brazilian National Studies and Project Funding Agency; FACEP, Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco–State of Pernambuco Science and Technology Funding Agency; CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico–National Counsel of Scientific and Technological Development; BNDES, Banco Nacional de Desenvolvimento Econômico e Social–Brazilian Development Bank; RHAE, Recursos Humanos Em Áreas Estratégicas–Human Resources in Strategic Areas; FAPESP, Fundação de Amparo à Pesquisa do Estado de São Paulo–The São Paulo State Funding Agency. | ||||||||
| Aché Laboratórios Farmacêuticos | 1966 | Private | R$1.77 ($951) | N/A | N/A | R$1.1 ($0.54) in 2006 | R$11.9 ($6.4) | 2,800 |
| BIOCANCER | 2004 | Private | N/A |  R$1.5 ($0.8) in 2005 and 2006 | Investors include FIR Capital, Biominas Foundation, Jardim Botânico Partners' Novarum Fund (all based in Belo Horizonte)/amounts not disclosed | Many foreign clientele | N/A | 15 |
| Biogene | 1995 | Private | R$0.17 ($0.094) | R$0.09 ($0.05) each year from FINEP and FACEPE | N/A | Just started exporting | R$0.098 ($0.053) | 4 (4) |
| Biolab Sanus Farmacêutica | 1996 | Privatec | R$335 ($180) | R$3.7 ($2) from FINEP; R$0.93 ($0.5) from CNPq and R$37 ($20) from BNDES at 6% per year interest (R&D funds shared with União Química) | Castro-Marques Group/R$56 ($30) in past 3 years | N/A | R$20.8 ($11.2); approximately half targeted for radical innovation | 1,542 (35) |
| BIOMM | 2002 | Publicly listed (On BOVESPA) | R$5.6 ($3) | N/A | N/A | 100% foreign clientele base | N/A | 15 (8) |
| COINFAR | 2001 | Private | No revenues yet | R$3.8 ($2) from FINEP (2005–2007) | Founding shareholders R$11 ($6) from 2002 to 2006 | N/A | R$3 ($1.6) expected for 2008 to 2009 | 6 internal with 20 researchers contracted in Brazilian universities |
| Cryopraxis Criobiologia | 2001 | Privated | R$22.3 ($12) in 2007 | None | None | N/A | N/A | 100 (10) |
| Eurofarma Laboratórios | 1972 | Private | R$826 ($444) | FINEP funded projects with Brazilian universities (amounts not disclosed) | N/A | N/A | R$37 ($20) | 2,300 (20) |
| FK Biotecnologia | 1999 | Private | R$0.37 ($0.2) in 2006; R$1.86 ($1) up to July 2007 | FINEP loan of R$0.14 ($0.075) in 2001. FINEP grants totaled R$ 3.7 ($2) from 2005 to 2007. R$0.07 ($0.04) in 2004 | Angel investors provided R$0.034 ($0.02) in 1999. First-round VC by RSTec venture funde R$1.16 ($0.62) in 2000 | Small amounts | R$1.86 ($1) | 25 (18) |
| Hebron Farmacêutica | 1990 | Private | R$56 ($30) | N/A | N/A | N/A | N/A | 550 |
| Intrials Latin America Clinical Research | 1999 | Private | N/A | N/A | 3 angel investors | Most foreign clientele | N/A | 30 |
| Katal Biotecnológica | 1994 | Private | R$4.6 ($2.5) in 2005 | N/A | Investment by Interteck Internacional Imp. e Exp. (São Paulo) f amount not disclosed | N/A | N/A | 35 (2) |
| Labtest Diagnóstica | 1971 | Private | R$31.6 ($17) in 2006 estimated at R$35 ($19) in 2007 | Low-interest loans from Bank of Development, Minas Gerais R$2.8 ($1.5) and BNDES R$2.4 ($1.3) | Undisclosed private sources provided R$0.9 ($0.49) | R$0.84 ($0.45) | R$1.15 ($0.62) | 110 (27) |
| Nortec Química | 1985 | Private (partly owned by government) | R$37 ($20) in 2006 | R$6 ($3.2) from FINEP | N/A | 10% of sales revenues | N/A | 180 (6) |
| Pele Nova Biotecnologia | 2003 | Private | R$1.86 ($1) in 2006; estimated at R$3.3 ($1.8) in 2007 | None | REIF Fund (managed by DGF Investments in São Paulo) and two angel investors/over R$7.4 ($4) | N/A | 35% of revenues and investments | 15 (4) |
| Recepta Biopharma | 2006 | Private | No revenues yet | R$16 ($8.6) from FINEP | Angel investors provided R$3.7 ($2) | N/A | R$6.1 ($3.3) | 4 (43 in partner institutions) |
| Scylla Bioinformatics | 2002 | Private | N/A | R$0.15 ($0.08) from each of FINEP and FAPESP, with some funds from CNPq | Votorantim Venture (São Paulo) provided R$0.5 ($0.27) | N/A | N/A | 8 |
| Silvestre Laboratories | 1984 | Privated | R$18.6 ($10) | None | None | N/A | R$3.7 ($2) | 65 (10) |
| União Química Farmacêutica Nacional | 1936 | Private | R$279 ($150) in 2006 | See Biolab information above | See Biolab information above | N/A | R$3.7 ($2) year (for incremental innovation) and R$10 ($5.4) per year for radical innovation | 1,800 (some R&D shared with Biolab) |
